Listed

ImmunityBio, Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 12, 2021 and accepted by EDGAR at Nov 12, 2021, 16:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$66.0kus-gaap:Revenues
Revenue9 months2021-01-01 to 2021-09-30$544.0kus-gaap:Revenues
Research and development3 months2021-07-01 to 2021-09-30$49.3mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$144.2mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-07-01 to 2021-09-30$29.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-01 to 2021-09-30$107.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-01 to 2021-09-30−$78.8mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$251.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-07-01 to 2021-09-30$3.6mus-gaap:InterestExpense
Interest expense9 months2021-01-01 to 2021-09-30$10.4mus-gaap:InterestExpense
Income tax3 months2021-07-01 to 2021-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30$8.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30−$87.6mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30−$255.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30−$0.22us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30−$0.66us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30−$0.22us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30−$0.66us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-30391,853,623 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-30386,606,200 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30−$202.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$23.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$64.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$94.5mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$214.4mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$65.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$404.4mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30−$188.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001326110-21-000009. Last ingested by Listed: Nov 9, 2026, 17:45 ET. Listed shows no prices and gives no investment advice.